Vertex Pharma stock sits at EUR 459.90 with USD 130.1 billion market cap
Published on 10/12/2026 at 16:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Vertex Pharma stock was EUR 459.90 at Lang & Schwarz on October 12, 2026 at 4:09 p.m. CEST.
- Vertex Pharmaceuticals carried a USD 130.1 billion market capitalization and a 29.82 P/E ratio on October 12, 2026.
- StreetAlpha listed a USD 576.00 average 12-month target from 9 analysts and November 2, 2026 as the next earnings date.
Vertex Pharma (ISIN US92532F1003) was trading at EUR 459.90 at Lang & Schwarz on October 12, 2026 at 4:09 p.m. CEST. The quote places the stock alongside a USD 130.1 billion market capitalization and a 29.82 P/E ratio in the latest market snapshot.
Price stays below the yearly high
The Lang & Schwarz price provides the current euro perspective for investors in Germany, while the Nasdaq quotation offers the home-market comparison. Vertex Pharmaceuticals was last at USD 512.51 on October 12, 2026 at 10:19 a.m. ET, with a 52-week range of USD 402.58 to USD 560.25.
The USD 130.1 billion market capitalization is dated October 12, 2026. The latest regular-session Nasdaq close was USD 510.08 on October 9, 2026, according to Global Banking and Finance Review.
Valuation and earnings calendar
Vertex Pharmaceuticals reported USD 3.3 billion of revenue in the second quarter of fiscal 2026, up 12.5 percent from the same quarter a year earlier, while net income reached USD 1.1 billion, up 6.5 percent. These figures and the period labeling are documented by GreekSoup.
StreetAlpha lists an average 12-month price target of USD 576.00 from 9 analysts, with 8 Buy ratings and 1 Hold rating. The same page identifies November 2, 2026 as the next earnings date and records RBC Capital raising its target from USD 570.00 to USD 576.00 on October 8, 2026, according to StreetAlpha.
Comparison with peers
Vertex Pharma (Lang & Schwarz, EUR): P/E 29.8, market capitalization USD 130.1 billion
Gilead Sciences (Nasdaq, USD): minus 0.07 percent, market capitalization USD 187.3 billion
Regeneron Pharmaceuticals (Nasdaq, USD): plus 2.38 percent, P/E 18.91, market capitalization USD 78.7 billion
Market data sets the frame
Vertex Pharmaceuticals combines a 38.0 percent operating margin over the trailing twelve months with a 29.82 P/E ratio, based on the latest reported figures. The second-quarter revenue increase of 12.5 percent gives the valuation a concrete operating comparison, while the USD 576.00 analyst average target and November 2 reporting date provide the next dated reference points.
The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.
Vertex Pharma market data
- Company: Vertex Pharmaceuticals Incorporated
- ISIN: US92532F1003
- Ticker: VRTX
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 12, 2026, 4:09 p.m. CEST: EUR 459.90
- Market capitalization: USD 130.1 billion (as of October 12, 2026)
- 52-week range: USD 402.58-560.25 (as of October 12, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Nasdaq-100
- Next earnings date: November 2, 2026
Market context: Market report Nasdaq Composite.
